This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / DOSIsoft launches DOSIsoft Theranostics
Business new entity launch

DOSIsoft launches DOSIsoft Theranostics

Analysis based on 7 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
60
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of DOSIsoft Theranostics is expected to positively impact the healthcare and software industries by accelerating innovation in personalized nuclear medicine. This could lead to advancements in cancer treatment and patient safety, potentially increasing demand for related technologies and services.

Healthcare Software Biotechnology
Event Summary

DOSIsoft Theranostics, a leader in dosimetry software, announced the launch of DOSIsoft Theranostics, a new independent entity dedicated to developing theranostics software for routine clinical adoption. This strategic move, announced ahead of SNMMI 2026, aims to accelerate innovation in radiopharmaceutical therapies and nuclear medicine, focusing on quantitative imaging, AI-driven workflows, and personalized care. Marc Uszynski, CEO of DOSIsoft Theranostics, stated that this reflects DOSIsoft Theranostics's long-term commitment to the rapidly expanding theranostics field. The new entity will leverage DOSIsoft Theranostics's PLANET platform, which is FDA 510(k) cleared and CE marked, to foster new partnerships and expand applications worldwide.

Entities Involved
priv
DOSIsoft Theranostics
DOSIsoft Theranostics launched a new dedicated entity, DOSIsoft Theranostics, to accelerate innovation in theranostics software, reflecting its long-term commitment to this expanding field.
Importance 100.0 Sentiment 60.0
per
Marc Uszynski
Marc Uszynski, CEO of DOSIsoft Theranostics, announced the creation of DOSIsoft Theranostics, emphasizing its strategic focus and agility to accelerate innovation and expand applications worldwide.
Importance 70.0 Sentiment 50.0
govactor
United States — Food and Drug Administration
The PLANET platform, central to DOSIsoft Theranostics, is FDA 510(k) cleared, indicating regulatory approval for its use.
Importance 20.0 Sentiment 0.0
alliance
European Union
The PLANET platform, central to DOSIsoft Theranostics, is CE marked, indicating compliance with European health, safety, and environmental protection standards.
Importance 20.0 Sentiment 0.0
oth
Curie Institute (Paris)
DOSIsoft Theranostics is a spin-off from Curie Institute (Paris), indicating a historical connection but no direct impact from this event.
Importance 10.0 Sentiment 0.0
oth
Thera4Care
DOSIsoft Theranostics is a contributing partner of the European Thera4Care project, showing its involvement in the broader theranostics ecosystem.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ European Union
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.